Health Canada Clears Novavax's Omicron-Targeted Vaccine For Children Above 12yrs
According to a report by Reuters, Novavax has announced that its updated COVID-19 vaccine, specifically designed to target the Omicron subvariant XBB.1.5, has received authorisation from Health Canada for individuals aged 12 years and older. The World Health Organization (WHO) had previously granted emergency use authorisation for the vaccine last month, which is tailored to address a descendant of the XBB lineage of the coronavirus, prevalent globally earlier this year, the report stated.
Reportedly, the updated vaccine received authorisation from the U.S. Food and Drug Administration and the European Commission in October. Novavax's original COVID shot obtained U.S. authorisation in July 2022, entering the market after the vaccines developed by Pfizer and Moderna had already been in use.
The approval from Health Canada extends the availability of the updated Novavax vaccine to a broader population, contributing to ongoing efforts to combat the evolving landscape of the COVID-19 virus.
